Contemporary in-hospital management strategies for acute decompensated heart failure

Cardiology in Review

Volumn 19, Issue 3, 2011, Pages 122-129

  Sanchez, Carlos E ^a   Richards, David R ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b RIVERSIDE METHODIST HOSPITAL   (United States)

Author keywords

acute heart failure; congestion; management; therapy

Indexed keywords

BUMETANIDE; CHLOROTHIAZIDE; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; METOLAZONE; NESIRITIDE; TORASEMIDE;

ACUTE DECOMPENSATED HEART FAILURE; ACUTE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; HOSPITAL READMISSION; HUMAN; MORTALITY; PROGNOSIS; REVIEW; RISK ASSESSMENT;

ACUTE DISEASE; CARDIOLOGY SERVICE, HOSPITAL; HEART FAILURE; HUMANS;

EID: 79955061249     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318214022b     Document Type: Review

References (65)

1. American Heart Association. Heart disease and stroke statistics-2006 Update. Dallas, TX: American Heart Association; 2006.
2. Fonarow GC; ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(suppl 7):S21-S30. (Pubitemid 37526952)
3. Philbin EF, Dec GW, Enkins PL, et al. Socioeconomic status as an independent risk factor for hospital readmission for heart failure. Am J Cardiol. 2001;87:1367-1371. (Pubitemid 32523020)
4. Hunt SA, Abraham WT, Chin MH, et al. American College of Cardiology Foundation; American Heart Association. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1-e90.
5. Nohria A, Tsnag SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797-1804. (Pubitemid 36584255)
6. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Eur Heart J. 2008;29:2388-2442.
7. Lindenfeld J, Albert NM, Boehmer JP, et al. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e475-e539.
8. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167. (Pubitemid 34764819)
9. Fonarow GC, Peacock WF, Phillips CO, et al. ADHERE Scientific Advisory Committee and Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49:1943-1950. (Pubitemid 46694287)
10. Logeart D, Thabut G, Jourdian P, et al. Pre-discharge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635-641. (Pubitemid 38229537)
11. Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure. Circulation. 2005;111:2454-2460.
12. Fonarow GC, Adams KF, Abraham WT, et al. ADHERE Scientific Advisory Committee, Study Groups and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572-580.
13. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527-1539.
14. Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J. 2010;31:703-711.
15. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-596.
16. Mullens W, Abrahams Z, Skouri HN, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol. 2008;51:300-306.
17. Felker GM, Leimberger JD, Califf RM, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail. 2004;10:460-466.
18. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581-2587. (Pubitemid 37443288)
19. Abraham WT, Fonarow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure. J Am Coll Cardiol. 2008;52:347-356.
20. Peacock WF, Emerman C, Costanzo MR, et al. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail. 2009;15:256-264.
21. Maisel AS, Peacock WF, McMullin N, et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE analysis. J Am Coll Cardiol. 2008;52:534-540.
22. Weintraub NL, Collins SP, Pang PS, et al. the American Heart Association Council on Clinical Cardiology and Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation. 2010;122:1975-1996.
23. Gheorghiade M, Shin DD, Thomas TO, et al. Congestion is an important diagnostic and therapeutic target in heart failure. Rev Cardiovasc Med. 2006;7(suppl l):S12-S24. (Pubitemid 44478683)
24. Cotter G, Metzkor E, Kaluski E, et al. Randomized trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary edema. Lancet. 1998;351:389-393. (Pubitemid 28064161)
25. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331-338. (Pubitemid 38176835)
26. Salvador DR, Rey NR, Ramos GC, et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2005:CD003178.
27. Felker GM. Diuretic Optimization Strategies Evaluation (DOSE) trial. Presented at: the ACC 10/i2 Summit; March 2010; Atlanta, GA.
28. Costanzo MR, Saltzberg M, O'Sullivan J, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005;46:2047-2051. (Pubitemid 41713590)
29. Costanzo MR, Guglin ME, Saltzberg MT, et al. UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675-683. (Pubitemid 46205043)
30. Shin DD, Brandimarte F, DeLuca L, et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol. 2007;99:4A-23A.
31. Mattu A, Martinez JP, Kelly BS. Modern management of cardiogenic pulmonary edema. Emerg Med Clin North Am. 2005;23:1105-1125. (Pubitemid 41400102)
32. Abraham WT, Adams KF, Fonarow GC, et al; ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the acute decompensated heart failure national registry (ADHERE). J Am Coll Cardiol. 2005;46:57-64. (Pubitemid 40905130)
33. Mullens W, Abrahams Z, Francis GS, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 2008;52:200-207. (Pubitemid 351915785)
34. Bhalla V, Willis S, Maisel AS. B-type natriuretic peptide: the level and the drug-partners in the diagnosis and management of congestive heart failure. Congest Heart Fail. 2004;10(1 suppl 1):3-27.
35. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
36. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491. (Pubitemid 40470642)
37. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-1905. (Pubitemid 40548187)
38. Arora RR, Venkatesh PK, Molnar J. Short and long term mortality with nesiritide. Am Heart J. 2006;152:1084-1090. (Pubitemid 44854791)
39. Yancy CW, Krum H, Massie BM, et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure. Results of the second follow-up serial infusions of nesiritide (FUSION II) trial. Circ Heart Fail. 2008;1:9-16.
40. Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 2007;50:1835-1840. (Pubitemid 350007964)
41. Hernandez AF. Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial (ASCEND-HF)-nesiritide or placebo for improved symptoms and outcomes in acute decompensated HF. In: American Heart Association 2010 Scientific Sessions (Late-Breaking Clinical Trials I); November 14, 2010; Chicago, IL.
42. Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J. 2008;25:205-209. (Pubitemid 351493056)
43. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J. 2007;153:98-104. (Pubitemid 44880871)
44. Cuffe MS, Califf RM, Adams KF Jr, et al. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME- CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized control trial. JAMA. 2002; 287:1541-1547.
45. Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, et al. Levosimendan: from basic science to clinical practice. Heart Fail Rev. 2009;14:265-275.
46. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202. (Pubitemid 34804646)
47. Moiseyev VS, Poder P, Andrejevs N, et al. RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422-1432. (Pubitemid 36285574)
48. Cleland JG, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8:105-110. (Pubitemid 43012109)
49. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007;297:1883-1891. (Pubitemid 46707842)
50. Packer M. Randomized multicenter evaluation of intravenous levosimendan efficacy versus placebo in the short-term treatment of decompensated heart failure trial-II (REVIVE-II). In: American Heart Association 2005 Scientific Sessions; November 13-16, 2005; Dallas, TX.
51. Gheorghiade M, Blair JE, Filippatos GS, et al. HORIZON-HF Investigators. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008;51: 2276-2285.
52. Shah SJ, Blair JE, Filippatos GS, et al. HORIZON-HF Investigators. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Am Heart J. 2009;157:1035-1041.
53. Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail. 2003;9:180-187. (Pubitemid 36734314)
54. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation. 2006; 113:2556-2564. (Pubitemid 43948035)
55. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Eng J Med. 1997;336:525-533.
56. Abu-Omar Y, Tsui S. Mechanical circulatory support for AMI and cardiogenic shock. J Card Surg. 2010;25:434-441.
57. Ziemba EA, John R. Mechanical circulatory support for bridge to decision: which device and when to decide. J Card Surg. 2010;25:425-433.
58. Shrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577-585. (Pubitemid 29384167)
59. Ferguson-Myrthil N. Novel agents for the treatment of hyponatremia. A review of conivaptan and tolvaptan. Cardiol Rev. 2010;18:313-321.
60. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319-1331. (Pubitemid 46513233)
61. Gheorghiade M, Konstam MA, Burnett Jr JC, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007;297:1332-1343. (Pubitemid 46513234)
62. Goldsmith SR, Elkayam U, Haught WH, et al. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail. 2008;14:641-647.
63. Conrad KP, Novak J. Emerging role of relaxin in renal and cardiovascular function. Am J Physiol Regul Integr Comp Physiol. 2004;287:R250-R261. (Pubitemid 38970272)
64. Grossman J, Frishman WH. Relaxin: a new approach for the treatment of acute congestive heart failure. Cardiol Rev. 2010;18:305-312.
65. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373:1429-1439.